Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 22
- 主要终点
- Expanded Disability Status Scale (EDSS)
研究概览
简要总结
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of MS
- •Progressive type MS
- •Voluntary participation
- •Age between 18-60 years
- •Cooperative
- •EDSS score ≥ 5.5
排除标准
- •Presence of another neurological disorder
- •Change in medication within the last 3 months
- •Relapse within the last 3 months
研究组 & 干预措施
Progressive Multiple Sclerosis
结局指标
主要结局
Expanded Disability Status Scale (EDSS)
时间窗: Baseline
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Standardized Mini-Mental Test
时间窗: Baseline
The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Symbol Digit Modalities Test
时间窗: Baseline
The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination. Score range: Typically 0 to \~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Multiple Sclerosis Impact Scale (MSIS-29)
时间窗: Baseline
Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Glial Fibrillary Acidic Protein (GFAP)
时间窗: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)
Neurofilament Light Chain (NfL)
时间窗: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Vascular Endothelial Growth Factor (VEGF)
时间窗: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
次要结局
未报告次要终点
研究者
Seda Nur Kemer
Lecturer, Department of Physiotherapy and Rehabilitation
Ondokuz Mayıs University